{"id":6990,"date":"2020-12-02T08:37:06","date_gmt":"2020-12-02T08:37:06","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=6990"},"modified":"2020-12-02T08:38:25","modified_gmt":"2020-12-02T08:38:25","slug":"son-dakika-biontech-ile-pfizerin-gelistirdigi-kovid-19-asisinin-yaygin-kullanimina-ilk-onay-ingiltereden-geldi","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/son-dakika-biontech-ile-pfizerin-gelistirdigi-kovid-19-asisinin-yaygin-kullanimina-ilk-onay-ingiltereden-geldi\/","title":{"rendered":"Son Dakika: Biontech ile Pfizer’in geli\u015ftirdi\u011fi Kovid-19 a\u015f\u0131s\u0131n\u0131n yayg\u0131n kullan\u0131m\u0131na ilk onay \u0130ngiltere’den geldi"},"content":{"rendered":"

#SonDakika<\/p>\n

\u0130ngiltere, T\u00fcrk bilim insan\u0131 Prof. Dr. U\u011fur \u015eahin’in kurucu orta\u011f\u0131 oldu\u011fu Alman biyoteknoloji firmas\u0131 BioNTech’in Amerikan ila\u00e7 \u015firketi Pfizer ile geli\u015ftirdi\u011fi yeni tip koronavir\u00fcs (Kovid-19) a\u015f\u0131s\u0131n\u0131n yayg\u0131n kullan\u0131m\u0131na onay verdi.<\/p>\n

BBC’nin haberine g\u00f6re, \u0130ngiltere \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu, “BNT162b2” a\u015f\u0131 aday\u0131n\u0131n yayg\u0131n kullan\u0131m i\u00e7in g\u00fcvenli oldu\u011funu bildirdi.<\/p>

\"\"<\/a><\/div>\n

B\u00f6ylece \u0130ngiltere, Kovid-19’a kar\u015f\u0131 geli\u015ftirilen bir a\u015f\u0131 aday\u0131na onay veren ilk \u00fclke oldu.<\/p>\n

Onay\u0131n ard\u0131ndan \u0130ngiltere’de gelecek haftadan itibaren y\u00fcksek \u00f6ncelikli guruplar\u0131n a\u015f\u0131lanmas\u0131na ba\u015flanmas\u0131 bekleniyor.<\/p>\n

\u0130ngiltere daha \u00f6nce a\u015f\u0131dan 40 milyon doz sat\u0131n almak \u00fczere \u00f6n anla\u015fma yapm\u0131\u015ft\u0131.<\/p>\n

Tescillenen ilk Kovid-19 a\u015f\u0131s\u0131<\/h4>\n

Mesajc\u0131 Ribo N\u00fckleik Asit (mRNA) temelli a\u015f\u0131 aday\u0131, d\u00fcnyada tescillenen ilk Kovid-19 a\u015f\u0131s\u0131 oldu.<\/p>\n

A\u015f\u0131, 10 ay gibi k\u0131sa bir s\u00fcrede klinik \u00f6ncesi geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131 ve 3 a\u015fama klinik denemeleri tamamlayarak onay almay\u0131 ba\u015fard\u0131.<\/p>\n

A\u015f\u0131, form\u00fcl\u00fcndeki RNA bile\u015fim sayesinde Kovid-19’u etkisiz k\u0131lan kan \u015fekeri enzimleri ile al\u0131mlay\u0131c\u0131-ba\u011flay\u0131c\u0131 \u0130mm\u00fcnoglobulin G antikorlar\u0131n\u0131 harekete ge\u00e7irmeyi, h\u00fccre d\u00fczeyinde ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi yaratan CD4+ ve CD8+ glikoproteinlerini art\u0131rmay\u0131 ama\u00e7l\u0131yor.<\/p>\n

ABD’de Pfizer, \u00c7in’de Fosun Pharma ila\u00e7 firmalar\u0131n\u0131n \u00fcretim lisans\u0131n\u0131 ald\u0131\u011f\u0131 a\u015f\u0131 aday\u0131 i\u00e7in 1’inci ve 2’nci a\u015fama klinik denemelerinin Almanya\u2019da y\u00fcr\u00fct\u00fclmesinin ard\u0131ndan 27 Temmuz\u2019da ABD, Arjantin ve Almanya\u2019n\u0131n aralar\u0131nda oldu\u011fu \u00fclkelerde 30 bin sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fcn\u00fcn kat\u0131lmas\u0131 hedefiyle 3. a\u015fama klinik denemeler ba\u015flat\u0131lm\u0131\u015ft\u0131.<\/p>\n

Vir\u00fcse kar\u015f\u0131 y\u00fczde 95 etkili<\/h4>\n

Pfizer ve BioNTech, 18 Kas\u0131m’da 3’\u00fcnc\u00fc a\u015fama klinik denemelerini tamamlad\u0131\u011f\u0131n\u0131, a\u015f\u0131 aday\u0131n\u0131n vir\u00fcse kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flamada y\u00fczde 95 etkili oldu\u011funu bildirmi\u015fti.<\/p>\n

\u015eirketler, a\u015f\u0131 aday\u0131n\u0131n acil kullan\u0131m\u0131na izin verilmesi i\u00e7in ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA) ile Avrupa \u0130la\u00e7 Ajans\u0131na (EMA) ba\u015fvurularda bulunmu\u015ftu.<\/p>\n

\u00c7ok say\u0131da \u00fclke \u00f6n anla\u015fmalar yapt\u0131
\n\u015eirketler, a\u015f\u0131n\u0131n tedariki i\u00e7in ABD, Avrupa Birli\u011fi (AB), \u0130ngiltere, Kanada ve Japonya ile anla\u015fmalar yapt\u0131. ABD h\u00fck\u00fcmeti, a\u015f\u0131 aday\u0131n\u0131n ba\u015far\u0131l\u0131 olmas\u0131 halinde 100 milyon doz a\u015f\u0131 sat\u0131n almak i\u00e7in 1,95 milyar dolar taahh\u00fct ederken, AB Komisyonu a\u015f\u0131dan 300 milyon doz, \u0130ngiltere 40 milyon doz, Kanada 20 milyon doz, Japonya ise 120 milyon doz sat\u0131n almak \u00fczere \u00f6n s\u00f6zle\u015fme imzalam\u0131\u015ft\u0131.<\/p>\n

T\u00fcrkiye 25 milyon doz almay\u0131 planl\u0131yor
\nSa\u011fl\u0131k Bakan\u0131 Fahrettin Koca, 25 Kas\u0131m’da, T\u00fcrkiye’nin a\u015f\u0131 aday\u0131ndan, 1 milyonu aral\u0131kta olmak \u00fczere k\u0131\u015f aylar\u0131nda 25 milyon doz sat\u0131n almak \u00fczere g\u00f6r\u00fc\u015fmeler y\u00fcr\u00fctt\u00fc\u011f\u00fcn\u00fc a\u00e7\u0131klam\u0131\u015ft\u0131.<\/p>\n

\u015eirket, a\u015f\u0131dan 2020 sonuna kadar 100 milyon ve 2021 sonuna kadar ise yakla\u015f\u0131k 1,3 milyar doz \u00fcretmeyi planl\u0131yor.<\/p>\n

AA<\/p>\n

\"\"<\/a><\/div>","protected":false},"excerpt":{"rendered":"

#SonDakika \u0130ngiltere, T\u00fcrk bilim insan\u0131 Prof. Dr. U\u011fur \u015eahin’in kurucu orta\u011f\u0131 oldu\u011fu Alman biyoteknoloji firmas\u0131 BioNTech’in Amerikan ila\u00e7 \u015firketi Pfizer ile geli\u015ftirdi\u011fi yeni tip koronavir\u00fcs (Kovid-19) a\u015f\u0131s\u0131n\u0131n yayg\u0131n kullan\u0131m\u0131na onay verdi. BBC’nin haberine g\u00f6re, \u0130ngiltere \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu, “BNT162b2” a\u015f\u0131 aday\u0131n\u0131n yayg\u0131n kullan\u0131m i\u00e7in g\u00fcvenli oldu\u011funu bildirdi. B\u00f6ylece \u0130ngiltere, Kovid-19’a kar\u015f\u0131 geli\u015ftirilen bir a\u015f\u0131 aday\u0131na onay veren ilk \u00fclke oldu. Onay\u0131n ard\u0131ndan \u0130ngiltere’de gelecek haftadan itibaren y\u00fcksek \u00f6ncelikli guruplar\u0131n a\u015f\u0131lanmas\u0131na ba\u015flanmas\u0131 bekleniyor. \u0130ngiltere daha \u00f6nce a\u015f\u0131dan 40 milyon doz sat\u0131n almak \u00fczere \u00f6n anla\u015fma yapm\u0131\u015ft\u0131. Tescillenen ilk Kovid-19 a\u015f\u0131s\u0131 Mesajc\u0131 Ribo N\u00fckleik Asit (mRNA) temelli a\u015f\u0131 aday\u0131, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-6990","post","type-post","status-publish","format-standard","hentry","category-ingiltere"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/6990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=6990"}],"version-history":[{"count":0,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/6990\/revisions"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=6990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=6990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=6990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}